A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB

Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Potter, J L, Capstick, T, Ricketts, W M, Whitehead, N, Kon, O M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Chest Clinic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345768/
https://www.ncbi.nlm.nih.gov/pubmed/24928813
http://dx.doi.org/10.1136/thoraxjnl-2014-205278
_version_ 1782359625849372672
author Potter, J L
Capstick, T
Ricketts, W M
Whitehead, N
Kon, O M
author_facet Potter, J L
Capstick, T
Ricketts, W M
Whitehead, N
Kon, O M
author_sort Potter, J L
collection PubMed
description Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs currently available in the UK to treat TB. These recommendations provide a structure through which healthcare professionals can better manage the complex drug regimens required for the treatment of MDR-TB; minimising the risk of adverse incidents and helping to improve patients’ tolerance, compliance and treatment completion.
format Online
Article
Text
id pubmed-4345768
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43457682015-03-18 A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB Potter, J L Capstick, T Ricketts, W M Whitehead, N Kon, O M Thorax Chest Clinic Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs currently available in the UK to treat TB. These recommendations provide a structure through which healthcare professionals can better manage the complex drug regimens required for the treatment of MDR-TB; minimising the risk of adverse incidents and helping to improve patients’ tolerance, compliance and treatment completion. BMJ Publishing Group 2015-03 2014-06-13 /pmc/articles/PMC4345768/ /pubmed/24928813 http://dx.doi.org/10.1136/thoraxjnl-2014-205278 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chest Clinic
Potter, J L
Capstick, T
Ricketts, W M
Whitehead, N
Kon, O M
A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB
title A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB
title_full A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB
title_fullStr A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB
title_full_unstemmed A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB
title_short A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB
title_sort uk-based resource to support the monitoring and safe use of anti-tb drugs and second-line treatment of multidrug-resistant tb
topic Chest Clinic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345768/
https://www.ncbi.nlm.nih.gov/pubmed/24928813
http://dx.doi.org/10.1136/thoraxjnl-2014-205278
work_keys_str_mv AT potterjl aukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT capstickt aukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT rickettswm aukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT whiteheadn aukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT konom aukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT potterjl ukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT capstickt ukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT rickettswm ukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT whiteheadn ukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb
AT konom ukbasedresourcetosupportthemonitoringandsafeuseofantitbdrugsandsecondlinetreatmentofmultidrugresistanttb

Ejemplares similares